PaxVax Obtains $62,000,000 Series B Funding

  • Feed Type
  • Date
    7/28/2014
  • Company Name
    PaxVax
  • Mailing Address
    3985A Sorrento Valley Boulevard San Diego, CA 92121 USA
  • Company Description
    PaxVax is a privately held, fully integrated vaccine company, based in Menlo Park, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact.
  • Website
    http://www.paxvax.com
  • Transaction Type
    Debt
  • Transaction Amount
    $62,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    This financing was secured as part of the company’s acquisition of the FDA-approved oral typhoid vaccine Vivotif® from Crucell Switzerland AG. Additional proceeds will be used to support clinical development, regulatory review and the expected global launch of PaxVax’s cholera vaccine candidate, PXVX0200, currently in Phase 3 clinical testing.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor

By posting a comment, you agree to our terms and conditions.